Related Experiment Video
Updated: Jul 5, 2026
13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
Antineutrophil cytoplasmic antibody-associated active scleritis
Lani T Hoang1, Lyndell L Lim, Brian Vaillant
1Oregon Health & Science University, Portland, USA.
Archives of Ophthalmology (Chicago, Ill. : 1960)
|May 14, 2008
Summary
Antineutrophil cytoplasmic antibody (ANCA) testing in scleritis patients indicates a higher likelihood of severe ocular disease and systemic disorders. Positive ANCA results often necessitate more aggressive treatment strategies for better patient outcomes.
Area of Science:
- Ophthalmology
- Rheumatology
- Immunology
Background:
- Scleritis is a serious ocular inflammatory condition.
- The role of antineutrophil cytoplasmic antibodies (ANCAs) in scleritis prognosis is not fully established.
Purpose of the Study:
- To investigate the prognostic value of ANCA testing in patients with scleritis.
- To compare clinical features, treatments, and systemic associations between ANCA-positive and ANCA-negative scleritis patients.
Main Methods:
- Retrospective review of 78 patients evaluated at a tertiary care center.
- Comparison of clinical data, systemic disease associations, and treatment regimens based on ANCA test results.
Main Results:
- ANCA-positive patients (14/78) were more likely to have associated systemic disorders (71% vs. 41%) and diagnosed vasculitis.
- Significantly higher rates of ocular complications, including keratopathy and vision loss (≥20/50), were observed in ANCA-positive patients.
- ANCA-positive patients required more aggressive therapies, including systemic corticosteroids and alkylating agents.
Conclusions:
- A significant proportion of scleritis patients test positive for ANCA.
- ANCA positivity in scleritis is associated with more severe ocular disease and undiagnosed systemic vasculitis.
- ANCA testing can be a valuable tool for guiding the evaluation and treatment of scleritis patients.
